Patents by Inventor Andrew G. Cole

Andrew G. Cole has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF
    Publication number: 20230312481
    Abstract: The present disclosure includes certain substituted (phthalazin-1-ylmethyl)ureas, N-(phthalazin-1-ylmethyl)amides, and analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
    Type: Application
    Filed: June 7, 2021
    Publication date: October 5, 2023
    Inventors: Andrew G. Cole, Bruce D. Dorsey, Benjamin J. Dugan, Yi Fan, Steven G. Kultgen, Eugen F. Mesaros, Michael J. Sofia
  • Heterocycle amines and uses thereof
    Patent number: 11773110
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Grant
    Filed: October 28, 2021
    Date of Patent: October 3, 2023
    Assignee: LIGAND PHARMACEUTICALS INCORPORATED
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME
    Publication number: 20230295115
    Abstract: The present disclosure includes substituted isoquinolinylmethyl amides, or analogues thereof, and compositions comprising the same, that can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
    Type: Application
    Filed: June 7, 2021
    Publication date: September 21, 2023
    Inventors: Andrew G. Cole, Bruce D. Dorsey, Benjamin J. Dugan, Yi Fan, Steven G. Kultgen, Eugen F. Mesaros, Michael J. Sofia
  • SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME
    Publication number: 20230143612
    Abstract: The present invention includes substituted 1,1?-biphenyl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the invention can be used to treat, ameliorate, or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the invention can be used to treat, ameliorate, and/or prevent cancer in a patient.
    Type: Application
    Filed: February 1, 2021
    Publication date: May 11, 2023
    Inventors: Vijay Ahuja, Yingzhi Bi, Andrew G. Cole, Bruce D. Dorsey, Yi Fan, Ramesh Kakarla, Sharon Marie Kirk, Duyan Nguyen, Seyma Ozturk, Jorge G. Quintero, Michael J. Sofia
  • SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME
    Publication number: 20230108906
    Abstract: The present disclosure includes in one aspect substituted arylmethyl ureas, substituted heteroarylmethyl ureas, or analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 6, 2023
    Inventors: Andrew G. Cole, Bruce D. Dorsey, Yi Fan, Steven G. Kultgen, Eugen F. Mesaros
  • SUBSTITUTED CYCLOPROPYL-2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME
    Publication number: 20230083973
    Abstract: The present disclosure includes novel substituted cyclopropyl-2,2?-bipyrimidinyl compounds, and compositions comprising the same. In certain embodiments, the compounds of the disclosure can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infection in a patient.
    Type: Application
    Filed: July 31, 2020
    Publication date: March 16, 2023
    Inventors: Shuai Chen, Andrew G. Cole, Bruce D. Dorsey, Benjamin J. Dugan, Yi Fan, Dimitar B. Gotchev, Jorge Quintero, Michael J. Sofia
  • SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME
    Publication number: 20230045421
    Abstract: The present invention includes substituted arylmethyl ureas and heteroarylmethyl-ureas, and compositions comprising the same, that can be used to treat and/or prevent hepatitis B virus (HBV) infections in a patient.
    Type: Application
    Filed: December 11, 2019
    Publication date: February 9, 2023
    Inventors: Andrew G. Cole, Yi Fan, Steven Kultgen, Eugen Mesaros
  • Substituted tetrahydrocyclopenta[C]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods using same
    Patent number: 11566002
    Abstract: The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infection in a patient.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: January 31, 2023
    Assignee: Arbutus Biopharma Corporation
    Inventors: Andrew G. Cole, Steven Kultgen
  • SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME
    Publication number: 20230019280
    Abstract: The present disclosure includes substituted isoindolinyl 2,2?-bipyrimidinyl compounds, analogues thereof, and compositions comprising the same, which can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) and/or hepatitis B virus (HBV)-hepatitis D virus (HDV) infection in a patient.
    Type: Application
    Filed: November 12, 2020
    Publication date: January 19, 2023
    Inventors: Shuai Chen, Andrew G. Cole, Bruce D. Dorsey, Benjamin J. Dugan, Yi Fan, Dimitar B. Gotchev, Ramesh Kakarla, Jorge Quintero, Michael J. Sofia
  • SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME
    Publication number: 20220125771
    Abstract: The present invention includes substituted polycyclic carboxylic acids, analogues thereof, and compositions comprising the same, which can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) in a patient.
    Type: Application
    Filed: January 15, 2020
    Publication date: April 28, 2022
    Inventors: Shuai Chen, Andrew G. Cole, Bruce D. Dorsey, Yi Fan, Dimitar B. Gotchev, Ramesh Kakarla, Sharon Marie Kirk, Jorge Quintero, Michael J. Sofia
  • HETEROCYCLE AMINES AND USES THEREOF
    Publication number: 20220119413
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Application
    Filed: October 28, 2021
    Publication date: April 21, 2022
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • Non-systemic TGR5 agonists
    Patent number: 11236055
    Abstract: The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: February 1, 2022
    Assignee: VENENUM BIODESIGN, LLC
    Inventors: Chia-Yu Huang, Brian F. McGuinness, Dongchuan Shi, Steven G. Kultgen, Jeffrey J. Letourneau, James R. Beasley, Philip D. Stein, Andrew G. Cole
  • Heterocycle amines and uses thereof
    Patent number: 11186593
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: November 30, 2021
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
    Patent number: 11098010
    Abstract: The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 24, 2021
    Assignee: Arbutus Biopharma Corporation
    Inventors: Andrew G. Cole, Bruce D. Dorsey, Ramesh Kakarla, Steven Kultgen, Jorge Quintero
  • SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME
    Publication number: 20210251991
    Abstract: The present disclosure includes substituted 2,2?-bipyrimidinyl compounds, analogues thereof, and compositions comprising the same, which can be used to treat and/or prevent hepatitis B virus (HBV) and/or hepatitis B virus (HBV)-hepatitis D virus (HDV) infection in a patient.
    Type: Application
    Filed: May 14, 2019
    Publication date: August 19, 2021
    Inventors: Shuai Chen, Andrew G. Cole, Bruce D. Dorsey, Benjamin J. Dugan, Yi Fan, Dimitar B. Gotchev, Ramesh Kakarla, Jorge Quintero, Michael J. Sofia
  • SUBSTITUTED TETRAHYDROCYCLOPENTA[C]PYRROLES, SUBSTITUTED DIHYDROPYRROLIZINES, ANALOGUES THEREOF, AND METHODS USING SAME
    Publication number: 20210179557
    Abstract: The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infection in a patient.
    Type: Application
    Filed: July 25, 2019
    Publication date: June 17, 2021
    Inventors: Andrew G. COLE, Steven KULTGEN
  • Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
    Patent number: 11001564
    Abstract: The present invention includes novel substituted bicyclic (such as 4-substituted-chromane-8-carboxamide compounds), and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: May 11, 2021
    Assignee: Arbutus Biopharma Corporation
    Inventors: Andrew G. Cole, Steven Kultgen
  • NOVEL NON-SYSTEMIC TGR5 AGONISTS
    Publication number: 20200308122
    Abstract: The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 1, 2020
    Applicant: Venenum Biodesign, LLC
    Inventors: Chia-Yu Huang, Brian F. McGuinness, Dongchuan Shi, Steven G. Kultgen, Jeffrey J. Letourneau, James R. Beasley, Philip D. Stein, Andrew G. Cole
  • HETEROCYCLE AMINES AND USES THEREOF
    Publication number: 20200216468
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Application
    Filed: January 7, 2020
    Publication date: July 9, 2020
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • toxin inhibitors
    Patent number: 10669242
    Abstract: The present invention relates to benzodiazepine derivative compounds of formula (I), or pharmaceutically acceptable salts thereof. The present benzodiazepine compounds are useful Clostridium difficile inhibitors in the treatment of Clostridium difficile infection in humans. The present invention provides a pharmaceutical composition containing benzodiazepine compounds of formula (I) and a method of making as well as a method of using the same in treating patients infected with Clostridium difficile infection by administering the same. The compounds of the present invention may be used in combination with additional antibiotics or anti-toxin antibody drugs.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 2, 2020
    Assignee: Venenum Biodesign, LLC
    Inventors: Jeffrey J. Letourneau, Andrew G. Cole, Brett A. Marinelli, Jorge G. Quintero